New challenges in hepatic fibrosis
- PMID: 8340600
- DOI: 10.1016/s0168-8278(05)80002-9
New challenges in hepatic fibrosis
Abstract
Treatment of hepatic fibrosis by simple and inexpensive therapies is a new challenge for the near future. Hepatic fibrosis which may lead to cirrhosis, is indeed associated with most chronic liver diseases and affects millions of people. During the last decade, major breakthroughs have been accomplished in the field of hepatic fibrosis including the discovery of key components of the extracellular matrix, the cellular origin of most matrix proteins, the molecular mechanisms involved in their synthesis and degradation, and the role of cytokines in fibrogenesis. Most of this progress came from the development of new techniques including in vitro model systems which have proven useful for investigating the molecular bases of fibrogenesis. From basic research to clinical application, two major fields are now actively explored: the search for reliable serum markers of fibrogenesis and the discovery of drugs that prevent cirrhosis. A recent approach to treat hepatic fibrosis is to use cytokines, e.g. interferons, that modulate extracellular matrix synthesis.
Comment on
-
alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers.J Hepatol. 1993 Apr;18(1):112-8. doi: 10.1016/s0168-8278(05)80018-2. J Hepatol. 1993. PMID: 8340603 Clinical Trial.
Similar articles
-
[Extracellular matrix, hepatic fibrosis and anti-fibrosis treatment].Acta Gastroenterol Belg. 1990 Mar-Apr;53(2):216-24. Acta Gastroenterol Belg. 1990. PMID: 2267901 Review. French.
-
Hepatic stellate cells as a target for the treatment of liver fibrosis.Semin Liver Dis. 2001 Aug;21(3):437-51. doi: 10.1055/s-2001-17558. Semin Liver Dis. 2001. PMID: 11586471 Review.
-
Liver fibrosis: from the bench to clinical targets.Dig Liver Dis. 2004 Apr;36(4):231-42. doi: 10.1016/j.dld.2004.01.003. Dig Liver Dis. 2004. PMID: 15115333 Review.
-
[Hepatic fibrogenesis].Rev Prat. 1997 Mar 1;47(5):482-6. Rev Prat. 1997. PMID: 9138408 French.
-
Liver fibrosis: Direct antifibrotic agents and targeted therapies.Matrix Biol. 2018 Aug;68-69:435-451. doi: 10.1016/j.matbio.2018.04.006. Epub 2018 Apr 12. Matrix Biol. 2018. PMID: 29656147 Review.
Cited by
-
Hepatic production of apolar aldehydes in rats with carbon tetrachloride-induced cirrhosis.Mol Cell Biochem. 1999 Aug;198(1-2):57-60. doi: 10.1023/a:1006998028528. Mol Cell Biochem. 1999. PMID: 10497878
-
The pathogenesis of alcoholic liver disease.Int J Exp Pathol. 1994 Apr;75(2):71-8. Int J Exp Pathol. 1994. PMID: 8199007 Free PMC article. Review. No abstract available.
-
CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.Br J Clin Pharmacol. 1995 Jan;39(1):71-6. doi: 10.1111/j.1365-2125.1995.tb04412.x. Br J Clin Pharmacol. 1995. PMID: 7756103 Free PMC article.
-
Supplementation of Citrus maxima Peel Powder Prevented Oxidative Stress, Fibrosis, and Hepatic Damage in Carbon Tetrachloride (CCl4) Treated Rats.Evid Based Complement Alternat Med. 2015;2015:598179. doi: 10.1155/2015/598179. Epub 2015 May 28. Evid Based Complement Alternat Med. 2015. PMID: 26106435 Free PMC article.
-
Liver morphology and function in visceral leishmaniasis (Kala-azar).J Clin Pathol. 1994 Jun;47(6):547-51. doi: 10.1136/jcp.47.6.547. J Clin Pathol. 1994. PMID: 8063939 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical